Health Policy Watch [10 January 2020]
“Mental health – among the ‘most neglected’ of neglected tropical disease issues, says DNDi scientist”
Geneva/Seattle – 25 November 2019
DNDi has been awarded $29.2 million to accelerate the development of innovative new drugs for patients in sub-Saharan Africa with sleeping sickness (human African trypanosomiasis – $15 million) and river blindness (onchocerciasis – $14.2 million) by the Bill & Melinda Gates Foundation These two parasitic diseases could be eliminated if new patient care tools are brought to bear.
Paris, France – 18 October 2019
Bertrand Walckenaer, Deputy CEO of the Agence Française de Développement (AFD), and Dr Bernard Pécoul, Executive Director of DNDi, signed an agreement today for a project to support the research and development of treatments for neglected tropical diseases. Implementing a strategy to develop suitable, affordable, and safe treatments is a major international challenge; more than one billion people in 149 countries are affected by these diseases. This project is funded by a EUR 8 million grant.
Paris, France – le 18 octobre 2019
Bertrand Walckenaer, Directeur délégué de l’Agence française de développement, a signé, ce jour, avec Dr. Bernard Pécoul, Directeur exécutif de DNDi, un projet d’appui à la recherche et au développement de traitements contre les maladies tropicales négligées. La mise en place d’une stratégie de développement de traitements adaptés, abordables et sûrs est un enjeu majeur à l’échelle internationale : plus d’un milliard de personnes réparties dans 149 pays sont touchées par ces maladies. Le projet est une subvention d’un montant de 8 millions d’euros.
27-29 October 2019
- Nathalie Strub-Wourgaft, NTD Director – workshops on sustainable elimination of NTDs and on co-creation and co-ownership of the UHC and SDG agendas
- Monique Wasunna, Director of the DNDi Africa Regional Office – workshop on co-creation and co-ownership of the UHC and SDG agendas
NewStatesman [27 August 2019]
“How the world is winning the fight against neglected tropical diseases”
23-27 September 2019
- Olaf Valverde, T.b. Rhodesiense HAT Leader – presentation on the challenges of active case detection for sleeping sickness elimination
- Junior Mudji, Investigator – presentation on the evolution of the nutritional status of children enrolled in a fexinidazole study
- Jose Dinanga, Laboratory Coordinator – presentation on strengthening diagnostic documentation procedures
Fexinidazole, the first all-oral treatment for sleeping sickness registered by Sanofi and developed in clinical trials led by DNDi, has been added to the World Health Organization’s Essential Medicines Lists for adults and children, for the treatment of both stages of the disease.
Health Policy Watch [9 July 2019]
“New cancer drugs top entries on WHO Essential Medicines List”
RTS [24 May 2019]
“Rencontre avec Bernard Pécoul, directeur d’une ONG tout à fait unique” – “Meeting with Bernard Pécoul, director of a very unique NGO”
Radio interview of Dr Bernard Pécoul, Executive Director, DNDi
Priorité Santé, RFI [24 May 2019]
“Les maladies tropicales négligées” – “Neglected tropical diseases”
Programme on neglected tropical diseases including an interview with Dr Bernard Pécoul, Executive Director at DNDi (from 14:48).
16-20 September 2019
- DNDi – one symposium on cutaneous leishmaniasis and one on mycetoma
- Nathalie Strub-Wourgaft, NTD Director – panel discussion on the future of research and development, satellite symposium on sleeping sickness
9-10 May 2019
- Fabiana Barreira, Chagas Senior Clinical Manager – presentation of the BENDITA trial for Chagas disease
- Nathalie Strub-Wourgaft, Director NTDs – presentation on registration steps for the new all oral sleeping sickness treatment
The Conversation [21 March 2019]
“Un médicament sans brevet pour vaincre enfin la maladie du sommeil” – “A drug without a patent to finally overcome sleeping sickness”
El País [28 February 2019]
“La mujer que cambió la historia de los medicamentos” – “The woman who changed the history of medicines”
Fexinidazole, the first all-oral treatment for both stages of HAT caused by T.b gambiense and DNDi’s first new chemical entity, was recommended by the European Medicines Agency in November and registered in Democratic Republic of Congo (DRC) in December 2018. The Phase II/III study on acoziborole opened new clinical sites in DRC and Guinea.